Bruce C. Tiu

Statistics

Publications

Citations

248

H-Index

Active since

2022

Affiliations

Massachusetts General Hospital(Current)

Harvard University

Johns Hopkins University

Dana-Farber Cancer Institute

Bruce C. Tiu is an author at Massachusetts General Hospital specializing in immune-mediated adverse events, immune checkpoint inhibitors, and oncology.

ORCID

Publications per year

2022–2023

Publications

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Kimberly Tang, Jayhyun Seo, Bruce C. Tiu et al. · JAMA Dermatology · 2022 · 130 citations · Full text

Medicine, Dermatology, Oncology +17

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

Bruce C. Tiu, Leyre Zubiri, James Iheke et al. · Journal for ImmunoTherapy of Cancer · 2022 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy

Kimberly Tang, Bruce C. Tiu, Guihong Wan et al. · JNCI Journal of the National Cancer Institute · 2022 · 21 citations · Full text

Life Sciences, Immunology, Oncology +17

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study

Bruce C. Tiu, Ian A. Strohbehn, Sophia Zhao et al. · The Oncologist · 2023 · 13 citations · Full text

Medicine, Immunology, Oncology +17

1–4 of 4